Jesus D Melgarejo1,2, Daniel C Aguirre-Acevedo3, Ciro Gaona1, Carlos A Chavez1, Gustavo E Calmón4, Eglé R Silva4, Gabriel A de Erausquin5,6, Mario Gil6,7, Luis J Mena8, Joseph D Terwilliger9,10,11,12, Humberto Arboleda13,14, Nikolaos Scarmeas15,16, Joseph H Lee10,15,17, Gladys E Maestre1,6,18,19. 1. Laboratory of Neuroscience, University of Zulia, Maracaibo, Venezuela. 2. Research Unit Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Sciences, KU University of Leuven, Leuven, Belgium. 3. Medical Research Institute, School of Medicine, University of Antioquia, Medellin, Colombia. 4. Instituto de Investigación de Enfermedades Cardiovasculares de la Universidad del Zulia, Facultad de Medicina, Universidad del Zulia, Maracaibo, Venezuela. 5. Department of Neurology, and Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA. 6. Alzheimer's Disease Resource Center for Minority Aging Research, University of Texas Rio Grande Valley, Brownsville, TX, USA. 7. Department of Psychological Science and Department of Neurosciences, University of Texas Rio Grande Valley, School of Medicine, Edinburg, TX, USA. 8. Department of Informatics, Universidad Politécnica de Sinaloa, Mazatlán, México. 9. Departments of Psychiatry and Genetics & Development, Columbia University Medical Center, New York, NY, USA. 10. Sergievsky Center & Department of Epidemiology, Columbia University Medical Center, New York, NY, USA. 11. Division of Medical Genetics, New York State Psychiatric Institute, New York, NY, USA. 12. Division of Public Health Genomics, National Institute for Health and Welfare, Helsinki, Finland. 13. Neurosciences Research Group, School of Medicine, Nacional University of Colombia, Bogotá, Colombia. 14. Genetic Institute, National University of Colombia, Bogotá, Colombia. 15. Taub Institute for Research on Alzheimer's Disease and the Aging Brain and Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA. 16. 1st Department of Neurology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 17. Department of Epidemiology, School of Public Health, Columbia University, New York, NY, USA. 18. Department of Neurosciences, University of Texas Rio Grande Valley School of Medicine, Brownsville, TX, USA. 19. Department of Human Genetics University of Texas Rio Grande Valley School of Medicine, Brownsville, TX, USA.
Abstract
BACKGROUND: Dementia of the Alzheimer's type (DAT) impacts Hispanics disproportionately, with almost a twofold elevated risk of developing DAT, as well as earlier onset of the disease, than in non-Hispanic Whites. However, the role of main risk factors for DAT, such as APOE-ɛ4 and blood pressure (BP) levels, remains uncertain among Hispanics. OBJECTIVE: To investigate the association of APOE-ɛ4 and BP levels, measures with 24-h ambulatory BP monitoring, with incidence of DAT in an elderly cohort of Hispanics. METHODS: 1,320 participants from the Maracaibo Aging Study, free of dementia at the baseline, and with ambulatory BP measurements and APOE genotype available were included. Adjusted Cox proportional models were performed to examine 1) the incidence of DAT and 2) the relationship between BP levels and DAT according to APOE genotypes. Models were adjusted by competing risk of death before the onset of DAT. Model performance was assessed by likelihood test. RESULTS: The average follow-up time was 5.3 years. DAT incidence was 5.8 per 1000 person-year. APOE-ɛ4 carriers had a higher risk of DAT. In unadjusted analyses, conventional, 24-h, and nighttime systolic BP levels were significantly higher in participants who developed DAT and of APOE-ɛ4 carriers (p < 0.05). After adjustment for competing risks, only higher nighttime systolic BP was associated with DAT incidence, but only among subjects carrying APOE-ɛ4. CONCLUSION: In this Hispanic population, both APOE-ɛ4 genotype and assessment of nocturnal systolic BP (rather than diurnal or office BP) were necessary to estimate DAT risk.
BACKGROUND:Dementia of the Alzheimer's type (DAT) impacts Hispanics disproportionately, with almost a twofold elevated risk of developing DAT, as well as earlier onset of the disease, than in non-Hispanic Whites. However, the role of main risk factors for DAT, such as APOE-ɛ4 and blood pressure (BP) levels, remains uncertain among Hispanics. OBJECTIVE: To investigate the association of APOE-ɛ4 and BP levels, measures with 24-h ambulatory BP monitoring, with incidence of DAT in an elderly cohort of Hispanics. METHODS: 1,320 participants from the Maracaibo Aging Study, free of dementia at the baseline, and with ambulatory BP measurements and APOE genotype available were included. Adjusted Cox proportional models were performed to examine 1) the incidence of DAT and 2) the relationship between BP levels and DAT according to APOE genotypes. Models were adjusted by competing risk of death before the onset of DAT. Model performance was assessed by likelihood test. RESULTS: The average follow-up time was 5.3 years. DAT incidence was 5.8 per 1000 person-year. APOE-ɛ4 carriers had a higher risk of DAT. In unadjusted analyses, conventional, 24-h, and nighttime systolic BP levels were significantly higher in participants who developed DAT and of APOE-ɛ4 carriers (p < 0.05). After adjustment for competing risks, only higher nighttime systolic BP was associated with DAT incidence, but only among subjects carrying APOE-ɛ4. CONCLUSION: In this Hispanic population, both APOE-ɛ4 genotype and assessment of nocturnal systolic BP (rather than diurnal or office BP) were necessary to estimate DAT risk.
Authors: I Skoog; B Lernfelt; S Landahl; B Palmertz; L A Andreasson; L Nilsson; G Persson; A Odén; A Svanborg Journal: Lancet Date: 1996-04-27 Impact factor: 79.321
Authors: Anthony G Chesebro; Jesus D Melgarejo; Reinier Leendertz; Kay C Igwe; Patrick J Lao; Krystal K Laing; Batool Rizvi; Mariana Budge; Irene B Meier; Gustavo Calmon; Joseph H Lee; Gladys E Maestre; Adam M Brickman Journal: Neurology Date: 2020-04-15 Impact factor: 9.910
Authors: Miia Kivipelto; Eeva-Liisa Helkala; Mikko P Laakso; Tuomo Hänninen; Merja Hallikainen; Kari Alhainen; Susan Iivonen; Arto Mannermaa; Jaakko Tuomilehto; Aulikki Nissinen; Hilkka Soininen Journal: Ann Intern Med Date: 2002-08-06 Impact factor: 25.391
Authors: Leon M Tai; Riya Thomas; Felecia M Marottoli; Kevin P Koster; Takahisa Kanekiyo; Alan W J Morris; Guojun Bu Journal: Acta Neuropathol Date: 2016-02-16 Impact factor: 17.088
Authors: Adam M Brickman; Frank A Provenzano; Jordan Muraskin; Jennifer J Manly; Sonja Blum; Zoltan Apa; Yaakov Stern; Truman R Brown; José A Luchsinger; Richard Mayeux Journal: Arch Neurol Date: 2012-12
Authors: Ellen M Wijsman; Nathan D Pankratz; Yoonha Choi; Joseph H Rothstein; Kelley M Faber; Rong Cheng; Joseph H Lee; Thomas D Bird; David A Bennett; Ramon Diaz-Arrastia; Alison M Goate; Martin Farlow; Bernardino Ghetti; Robert A Sweet; Tatiana M Foroud; Richard Mayeux Journal: PLoS Genet Date: 2011-02-17 Impact factor: 5.917
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566